Cyp11 A1 Inhibitor For Use In The Treatment Of Prostate Cancer

Abstract: The invention relates to the use of an activating AR gene alteration as a biomarker for identifying prostate cancer patients who have a higher probability to be responsive to the treatment with a CYP11A1 inhibitor. The invention also relates to a method for treating prostate cancer comprising a) obtaining or having obtained a sample from the patient; b) assaying or having assayed a sample to determine whether the patient has an activating AR gene alteration and c) if the patient has an activating AR gene alteration, treating the patient with a therapeutically effective amount of a CYP11A1 inhibitor.

Patent Information

Application #

Filing Date

28 March 2024

Publication Number

45/2024

Publication Type

INA

Invention Field

CHEMICAL

Status

Email

Parent Application

Applicants

ORION CORPORATION

Orionintie 1 02200 Espoo

Inventors

1. IKONEN, Tarja

c/o ORION CORPORATION P.O.Box 65 02101 Espoo

2. VUORELA, Annamari

c/o ORION CORPORATION P.O.Box 65 02101 Espoo

Specification

Documents

Application Documents

#	Name	Date
1	202417025529-STATEMENT OF UNDERTAKING (FORM 3) [28-03-2024(online)].pdf	2024-03-28
2	202417025529-REQUEST FOR EXAMINATION (FORM-18) [28-03-2024(online)].pdf	2024-03-28
3	202417025529-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [28-03-2024(online)].pdf	2024-03-28
4	202417025529-FORM 18 [28-03-2024(online)].pdf	2024-03-28
5	202417025529-FORM 1 [28-03-2024(online)].pdf	2024-03-28
6	202417025529-DRAWINGS [28-03-2024(online)].pdf	2024-03-28
7	202417025529-DECLARATION OF INVENTORSHIP (FORM 5) [28-03-2024(online)].pdf	2024-03-28
8	202417025529-COMPLETE SPECIFICATION [28-03-2024(online)].pdf	2024-03-28
9	202417025529-FORM-26 [26-04-2024(online)].pdf	2024-04-26
10	202417025529-Proof of Right [29-05-2024(online)].pdf	2024-05-29
11	202417025529-FORM 3 [27-09-2024(online)].pdf	2024-09-27
12	202417025529-GPA-050825.pdf	2025-08-08
13	202417025529-Correspondence-050825.pdf	2025-08-08